Ubrogepant
Calcitonin Gene-related Peptide Receptor Antagonist — NERVOUS SYSTEM
Also known as: ubrelvy
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ubrogepant is an onp drug in the Calcitonin Gene-related Peptide Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Calcitonin Gene-related Peptide Receptor Antagonists. DrugCentral lists 1 molecular target, including CALCRL. Recorded indications include Migraine.
- Approval status: onp (first approved 2019 by the FDA).
- Drug class: Calcitonin Gene-related Peptide Receptor Antagonist.
- Mechanism of action: Calcitonin Gene-related Peptide Receptor Antagonists.
- Molecular targets: CALCRL (1 listed in DrugCentral).
- Indications: Migraine.
- ATC code: N02CD04 (Calcitonin gene-related peptide (CGRP) antagonists).
- Molecular formula: C29H26F3N5O3; molecular weight 549.55 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Migraine
Mechanism & targets
| Mechanism of action (MoA) | Calcitonin Gene-related Peptide Receptor Antagonists |
|---|---|
| Established pharmacologic class | Calcitonin Gene-related Peptide Receptor Antagonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Calcitonin gene-related peptide type 1 receptor | CALCRL | antagonist | Ki 10.20 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-12-23 | FDA | — | ALLERGAN |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N02CD04 | NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Migraine | 143.2 |
| Cervicogenic headache | 88.3 |
| Pineal gland cyst | 87.5 |
| Migraine without aura | 78.2 |
| Drug ineffective | 71.2 |
| Headache | 66.4 |
| Product administration interrupted | 53.4 |
| Therapeutic response shortened | 52.1 |
| Drug effect less than expected | 46.1 |
| Device difficult to use | 45.0 |
| Tension headache | 42.4 |
| Nausea | 41.6 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Ubrogepant is on its molecule page.
| Molecular formula | C29H26F3N5O3 |
|---|---|
| Molecular weight | 549.55 g/mol |
| CAS number | 1374248-77-7 |
| InChIKey | DDOOFTLHJSMHLN-ZQHRPCGSSA-N |
| PubChem CID | 68748835 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ubrogepant used for?
DrugCentral lists the following indications for Ubrogepant: Migraine.
How does Ubrogepant work?
Ubrogepant is classified as Calcitonin Gene-related Peptide Receptor Antagonists; its molecular targets in DrugCentral include CALCRL (antagonist).
When was Ubrogepant first approved?
Ubrogepant was first approved by the FDA in 2019.
What drug class does Ubrogepant belong to?
Ubrogepant is in the Calcitonin Gene-related Peptide Receptor Antagonist class.
What is the chemical formula of Ubrogepant?
Ubrogepant has the molecular formula C29H26F3N5O3 and a molecular weight of 549.55 g/mol.
Browse: all drugs starting with U · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5361 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2364638 — compound record and bioactivity
- PubChem CID 68748835 — chemical identifiers
- DrugBank DB15328 — drug record
- FDA UNII AD0O8X2QJR — substance identity
- DailyMed: FDA labels for Ubrogepant — current prescribing information (label search)
- UniProt Q16602 (CALCRL) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.